Article info

Download PDFPDF
Original research
Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis

Authors

  • Leonardo Bottolo Department of Medical Genetics, University of Cambridge, Cambridge, UK The Alan Turing Institute, London, UK MRC Biostatistics Unit, Cambridge, UK PubMed articlesGoogle scholar articles
  • Suzanne Miller Division of Respiratory Medicine, NIHR Biomedical Research Centre, Biodiscovery Institute and Nottingham Molecular Pathology Node, University of Nottingham, Nottingham, UK PubMed articlesGoogle scholar articles
  • Simon R Johnson Division of Respiratory Medicine, NIHR Biomedical Research Centre, Biodiscovery Institute and Nottingham Molecular Pathology Node, University of Nottingham, Nottingham, UK National Centre for Lymphangioleiomyomatosis, Nottingham University Hospitals NHS Trust, Nottingham, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Simon R Johnson, Division of Respiratory Medicine, NIHR Biomedical Research Centre and Nottingham Molecular Pathology Node, University of Nottingham, Nottingham NG7 2UH, UK; simon.johnson{at}nottingham.ac.uk
View Full Text

Citation

Bottolo L, Miller S, Johnson SR
Sphingolipid, fatty acid and phospholipid metabolites are associated with disease severity and mTOR inhibition in lymphangioleiomyomatosis

Publication history

  • Received October 23, 2019
  • Revised March 26, 2020
  • Accepted April 16, 2020
  • First published May 28, 2020.
Online issue publication 
July 15, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.